Translating Next-Generation Science Into Transformative Gene TherapiesLearn About Our Programs

Encoded Therapeutics to Present Interim Phase 1/2 Clinical Data on ETX101, the First One-time Gene Therapy in Development for Dravet Syndrome, at the 2025 American Epilepsy Society …

Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Our diversity – whether gender, ethnicity, sexual …

Programs Encoded is building an internally developed pipeline of best- and potentially first-in-class therapies focused on neurological disorders.

Encoded’s state-of-the art GMP facility in North Carolina was completed in 1Q25. Designed to support the production of multiple gene therapies, the facility enhances Encoded’s strategic …

Encoded offers competitive pay, an equity program and benefits. We provide the support that team members need at work to succeed, and we give back the benefits and perks to maintain …

Ever wondered what it takes to make a gene therapy? Join us on a virtual lab tour at Encoded’s headquarters in South San Francisco. Meet a few of our talented scientists ready to explain …

Encoded Therapeutics is a clinical-stage genetic medicines company developing one-time therapies for severe neurological disorders. Our vector engineering platform enables highly …

Encoded will be providing additional updates on its research pipeline, which is focused on both rare genetic and common disease programs, in addition to clinical progress with ETX101 for …

Encoded’s innovative AAV-mediated miRNA platform offers a promising strategy for long-term knockdown of target genes in the central and peripheral nervous systems.